Now Playing
Opinion|Videos|September 28, 2023
Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
Author(s)Ajai Chari, MD, PhD
Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.
Advertisement
Episodes in this series
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5